Lubiprostone

Overview

Lubiprostone is a chloride channel activator used in the treatment of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation. It increases intestinal fluid secretion, thereby improving fecal transit.

API suppliers (8)

Suppliers of Lubiprostone backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• APOTEX PHARMACHEM INC1 active DMF
• Dr. Reddy's Laboratories Ltd.India1 active DMF
• Sun Pharmaceutical Industries LimitedIndia1 active DMF
• EVERLIGHT CHEMICAL INDUSTRIAL CORPTaiwan1 active DMF
• APOTEX PHARMACHEM INC1 active DMF
• Dr. Reddy's Laboratories Ltd.India1 active DMF
• FIS FABBRICA ITALIANA SINTETICI SPA
• Taro Pharmaceutical Industries Ltd.Israel

Patent & exclusivity (US)

Per the FDA Orange Book (12 approved US products), the latest listed US patent on Lubiprostone expires 24 Oct 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas